Attorneys from firms in Dallas and Houston secured a $42 million jury verdict on patent infringement for a state university and bioengineering company against Boston Scientific Corp.

The trial in the U.S. District Court for the District of Delaware concluded with plaintiff attorneys prevailing on patent infringement claims related to a biodegradable polymer fiber drug delivery system that was incorporated into Massachusetts-based Boston Scientific’s SYNERGY branded coronary stents.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]